Utilization of gabapentin by people in treatment for substance use disorders in Belgium (2011-2014): a cross-sectional study.

Last updated on 3-1-2023 by Lieke Vervoort

Public Access


Peer reviewed scientific article



Article written during project(s) : 


Background: Although gabapentin has been licensed in the European Union only for neuropathic pain and epilepsy for patients who have partial seizures, it has also been prescribed in treatment for substance use disorders. Many studies report the potential risk of abuse of gabapentin by people with substance use disorders. The objective of this paper is to determine if people who have been in treatment for substance use disorders bought gabapentin in a time span that could indicate consumption at a dose that exceeded the maximum approved dose of 3600 mg/day. Methods: This analysis is …

Associated health topics:

QR code

QR code for this page URL